Zhang, X., Guo, Y., Liu, X., Chen, Y., Huang, W., Zheng, B., Yan, W., Xu, Y., Wang, C., Wang, Y., Wang, J., Yu, L., Luo, Z. (2026). Sintilimab (PD-1 antibody) plus gemcitabine and docetaxel (GT) as first-line or later-line therapy in patients with advanced epithelioid sarcoma: A prospective, multicenter, single-arm, phase II clinical study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.11574